drugset / Trial / NCT07240857
A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer
Phase 0
Enrolling by invitation
18 enrolled
Zhejiang University
Orig Stone Biotech(Zhejiang) Co.,Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
An exploratory clinical study evaluating the safety and efficacy of ACT#001 chimeric antigen receptor T-cell (CAR-T cell) local injection in the treatment of castration-resistant prostate cancer.
Timeline
- Start
- 2026-04-12
- Primary completion
- 2026-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT#001-PSMA CAR-T | Cell therapy | 1.8e+07 cells | Other |
| Subject | ACT#001-PSMA CAR-T | Cell therapy | 5e+07 cells | Other |
| Subject | ACT#001-PSMA CAR-T | Cell therapy | 1e+08 cells | Other |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |